Patients with type 2 diabetes mellitus (T2DM) suffer from chronic and non-healing wounds due to diabetes-induced peripheral arterial occlusive disease. Cell-based therapies employed to enhance the regeneration of skin wounds include treatment with the CD34+ fraction of blood, which includes hematopoietic stem cells (HSCs), endothelial precursor cells (EPCs), and circulating angiogenic cells (CACs) [1].
Widecells Group (LON:WDC) are leading a transformation in cord blood banking and stem cell treatment; making cord blood banking more accessible through insurance coverage, and increasing the availability of cord blood for transplants.